BIOGEN for BIOGEN
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
IP protections for biologics and pharmaceuticals, consistent with U.S. law, to be included in trade agreements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHANIE A. DYSON New | Deputy Office Director, OSORA CMS Special Assistant, COO, CMS |
| JOHN RAYMOND GIBSON | — |
Taxation/Internal Revenue Code TAX
Corporate tax requirements and jobs: Domestic and international tax policies that protect and incentivize U.S. based research and manufacturing jobs including the net cost of Biogen R & D and well as percentage of revenue spent on R &D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHANIE A. DYSON | Deputy Office Director, OSORA CMS Special Assistant, COO, CMS |
| JOHN RAYMOND GIBSON New | — |
Copyright/Patent/Trademark CPT
S.1416 - Affordable Prescriptions for Patients Act of 2019 pertaining to the U.S. Patent system and well as patent law as it pertains to the IP system/process.SEC. 106. RESTORATION OF PATENTS AS PROPERTY RIGHTS. Entire Bill with particular emphasis on Secti 2, product hoping and patent thickening
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHANIE A. DYSON New | Deputy Office Director, OSORA CMS Special Assistant, COO, CMS |
| JOHN RAYMOND GIBSON | — |
Health Issues HCR
1. The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 (entire bill) -- 2. H.R. 3, Lower Drug Costs Now Act of 2019 (entire bill 3. Biosimilars Policy (no Bill). Advocacy for policy supporting/ that will spur the entry of biosimilars into the United States that will provide the Headroom for Innovation and is additive to the drug pricing policy debate. 4. Prescription Pricing for People Act (S. 1227/H.R. 2376) -SEC. 3. STUDY OF PHARMACEUTICAL SUPPLY CHAIN INTERMEDIARIES AND MERGER ACTIVITY as it pertains to PBMS and the supply chain. 5. Drug Rebate regulation - (no Bill) -Discussion regarding the Administrations withdrawal Harmful Drug Rebate Safe Harbor Rule, CBO Estimates, 6. Issues related to state based Newborn Screening Programs and tests (no Bill) 7. Scientific and Medical Innovation (no bill) - Issues related to product failure and economic implications to Biogen and Innovation in general 8. S.1416 - Affordable Prescriptions for Patients Act of 2019 (entire bill) with particular emphasis on Section 2 : Product Hoping and Patent Thickening
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHANIE A. DYSON New | Deputy Office Director, OSORA CMS Special Assistant, COO, CMS |
| JOHN RAYMOND GIBSON | — |
Medicare/Medicaid MMM
Issues related to changes in the Medicare Part B reimbursement system; issues related to changes in Iternational Pricing Index proposal; and Administration and Congressional proposal to address rebates in the Medicare Part D program the Prescription Drug Pricing Reduction Act (PDPRA) of 2019 andH.R. 3, Lower Drug Costs Now Act of 2019).
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEPHANIE A. DYSON New | Deputy Office Director, OSORA CMS Special Assistant, COO, CMS |
| JOHN RAYMOND GIBSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.